MolecularMD Licenses IP from NYU, MSKCC | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostic test developer MolecularMD has licensed from New York University and Memorial Sloan-Kettering Cancer Center a patent covering technology that may be used in a PCR-based assay to help guide cancer treatment, the company said Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.